What happened
Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) plans a Phase 3 trial of silevertinib after an FDA meeting on Oct. 1.
Silevertinib is an investigational, brain-penetrant inhibitor of the epidermal growth factor receptor (EGFR). The company says the FDA feedback supports a potential accelerated approval, based on central nervous system objective response rate (CNS-ORR). The approval would cover untreated patients with non-small cell lung cancer (NSCLC) whose tumors carry non-classical EGFR mutations.
Black Diamond announced the plan on Nov. 10 with updated Phase 2 data and third-quarter results. CEO Mark Velleca said the company believes the feedback supports a clear path to potential accelerated and full approval.
Key numbers
| Metric | Latest | Change | Source |
|---|---|---|---|
| CNS-ORR, patients with untreated brain metastases (16 patients, 7 evaluable by RANO-BM) | 86% | SEC 8-K Exhibit 99.1 | |
| Median progression-free survival, all 43 patients | 15.0 months | SEC 8-K Exhibit 99.1 | |
| Cash, cash equivalents and investments (prior figure is Dec. 31, 2025) | $102.0 million | from $128.7 million, -$26.6 million | Calculated from SEC 8-K Exhibit 99.1 |
| Net loss, third quarter | $10.0 million | from $8.5 million, +17.8% | Calculated from SEC 8-K Exhibit 99.1 |
| Net cash used in operations, third quarter | $8.3 million | from $7.9 million, +5.1% | Calculated from SEC 8-K Exhibit 99.1 |
Read more: Black Diamond Therapeutics (BDTX) company research
What the Phase 2 data show
The 86% brain response rate carries the update, but it rests on few patients. It is the CNS-ORR among patients with untreated brain metastases. That group had 16 patients, and 7 were evaluable by the RANO-BM criteria.
Systemic median progression-free survival (mPFS) in that group was 12.2 months. Across all 43 patients dosed at 200 mg once daily, the response rate was 60% and mPFS was 15.0 months. Median follow-up was 15.9 months as of an Oct. 7 data cutoff.
Among 24 patients without brain metastases, mPFS was 23.5 months and no patient had progression in the brain. Eighteen patients remained on therapy, the longest at 26.2 months. The company reported no new safety signals.
The company says mPFS in patients with untreated brain metastases is double that of currently available EGFR TKIs. But the data come from a single-arm trial. The filing says no head-to-head trials have been conducted and cross-trial comparisons are limited.
Stock perps: every US stock that trades as a perpetual future, by leverage, live
The planned Phase 3 design
The planned global trial would enroll 300 patients with non-classical EGFR mutations and untreated brain metastases. They would be randomized 1 to 1 to silevertinib at 150 mg once daily or to physician's choice of osimertinib or afatinib.
The primary endpoints are CNS-ORR for potential accelerated approval and systemic progression-free survival for potential full approval. The FDA indicated that systemic response rate and overall survival must be evaluated. The aim is to show similarity to the control arm and no evidence of a survival detriment.
The trial would also include an 80-patient single-arm cohort without brain metastases and a 20-patient single-arm cohort with leptomeningeal disease.
Why it matters
OptimistFi has argued that the stock works only if the MasterKey programs produce partnerable clinical evidence before cash runway and dilution become the main story. The update strengthens that view. It pairs response and progression data with a registration path the company discussed with the FDA.
The balance sheet gives the company time to reach it. Cash, cash equivalents and investments were $102.0 million at Sept. 30. That is down $26.6 million from $128.7 million at Dec. 31, 2025. The company expects the cash to fund operations into the second half of 2028.
Quarterly losses are widening. Net loss for the third quarter was $10.0 million, up 17.8% from $8.5 million a year earlier. Operations used $8.3 million of cash, against $7.9 million.
General and administrative expenses rose to $5.1 million from $3.5 million on higher IP-related costs and non-income tax expense. Research and development expenses fell to $7.0 million from $7.4 million as the NSCLC Phase 2 trial progressed. Start-up costs for the glioblastoma trial partly offset that decline.
The filing's forward-looking statements also refer to a proposed offering. They raise the question of whether its proceeds would be enough to fund the Phase 3 program through the CNS-ORR readout. That bears directly on the dilution side of OptimistFi's case.
The risks are in the filing. Interim data may change as more patient data become available. The FDA feedback is not binding, so the agency may change its views or require more data or trials.
What's next
Before the Phase 3 trial can open, safety data from enough patients in Cohort 4 must go to the FDA. Cohort 4 is enrolling 20 frontline patients at the planned pivotal dose. Its first patient was dosed in the third quarter.
The company says Phase 3 could start in the second quarter of 2027, with preliminary data expected in 2028 on that timing. A clean Cohort 4 safety package would keep that schedule. An FDA request for more data or trials would weaken it.
In newly diagnosed EGFRvIII-positive glioblastoma, the randomized Phase 2 portion dosed its first patient in the fourth quarter of 2026. Interim progression-free survival data are expected in the first half of 2028.
More from OptimistFi
- BDTX stock: research and coverage of Black Diamond Therapeutics
- Stock research on every company OptimistFi covers
From OptimistFi Perps
- Open interest live: crypto and stock perps by exchange
- All perp markets: price, open interest and funding by venue
- Futures calculator: liquidation price, PnL and fees by exchange
- Perp funding rates live: what longs and shorts pay on every venue
- Stock perps vs tokenized stocks: how US shares trade around the clock
Sources
- Black Diamond Therapeutics press release (Exhibit 99.1 to Form 8-K), Nov. 10, 2026 — Phase 2 results, FDA End-of-Phase 2 feedback, Phase 3 plan, third-quarter 2026 financial results and cash runway guidance.
- Black Diamond Therapeutics Form 8-K, Nov. 10, 2026 — Item 2.02 current report furnishing the press release as Exhibit 99.1.
Explore OptimistFi research on Black Diamond Therapeutics, Inc.: https://optimistfi.com/stocks/BDTX
Browse Black Diamond Therapeutics, Inc. company coverage and explore the OptimistFi Thesis-Break Engine.
Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.
Find available research on the Black Diamond Therapeutics, Inc. company page.
Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.
